Gene Tek's anti-PD-L1 mono-antitherapy Tecentriq (atezolizumab) gets FDA approval
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Roche's Genentechcompany,,http:// announcedthat its anti-PD-L1 mono-antitherapy Tecentriq (atezolizumab) had been approved by theFDA(http://, and that chemotherapy had become a first-line treatment for a wide range of small cell lung cancer (ES-SCLC)Tecentriq is currently the only tumor immunotherapy approved for first-line treatment of ES-SCLC, and the first time in more than 20 years that ES-SCLC patients have been given a new first-line treatment optionof TecentriqGene Tecentriq is a monoclonal antibody that targets binding PD-L1 to reactivate T cells by inhibiting PD-L1Tecentriq has been approved several times for the treatment of urinary skin cancer, non-small cell lung cancer, and triple-negative breast cancer, based on different indicationsThe approval of the first-line treatment for advanced small cell lung cancer is based on tecentriq's results in the clinical phase 3 IMpower133trial(http://data showed that in the intended treatment group, the use of Tecentriq combined chemotherapy (caplatinum and etoposide) significantly increased the survival rate of patients, with a median total survival of 12.3 months, higher than simple chemotherapy (10.3 months)In addition, chemotherapy combined with Tecentriq can significantly reduce the risk of disease deterioration or death, and the non-progressive survival is higher than that of chemotherapy aloneThe safety of combination therapy is consistent with the known safety of Tecentriq
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
